In fact, in pancreatic cancer cells, mutant KRAS activates DYRK1B via RAC1, a member of the RHO family [98] and the combinatory depletion of DYRK1B and KRAS led to strongly reduced cancer cell viability [98], which is of high interest in light of recently developed small molecule KRAS inhibitors [99]. Here, DYRK1B is linked to cancer.